

13. Fukuda M. The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. *Diabetes*. 2021;70(9):1929-1937.
14. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. *Nat Clin Pract Endocrinol Metab*. 2005;1(1):22-31.
15. Novikoff A, Müller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. *Peptides*. 2023;165:171003.
16. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387(3):205-216.
17. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. *Lancet Lond Engl*. 2022;400(10366):1869-1881.
18. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. *N Engl J Med*. 2023;389(6):514-526.
19. Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. *Kidney Int Rep*. 2025;S2468024925001925.
20. Eli Lilly and Company. TRIUMPH-1 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT05929066>
21. Eli Lilly and Company. TRIUMPH-2 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT05929079>.
22. Eli Lilly and Company. TRIUMPH-3 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT05882045>.
23. Eli Lilly and Company. TRIUMPH-4 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT05931367>.
24. Eli Lilly and Company. TRIUMPH-OUTCOMES [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT06383390>.
25. Eli Lilly and Company. TRANSCEND-T2D-1 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT06354660>.
26. Eli Lilly and Company. TRANSCEND-T2D-2 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT06260722>.
27. Eli Lilly and Company. TRANSCEND-T2D-3 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: <https://clinicaltrials.gov/study/NCT06297603>.
28. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. *Nat Med*. 2024;30(7):2037-2048.
29. Lyons SA, Beaudry JL. Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases. *Endocrinology*. 2023;164(11):bqad153.
30. Heerspink HL, Lu Z, Du Y, et al. 754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity – A Post-Hoc Analysis of Two Phase 2 Trials. *Diabetes*. 2024;73(Supplement_1):754-P.
31. Lilly E. A phase 2b, double-blind study to investigate the effect of LY3437943 on renal function in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes [Internet]. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: <https://clinicaltrials.gov>.
32. Deravi M, Piszczatoski C, Phillips B, et al. The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. *J Pharm Technol*. 2024;40(6):300-305.
33. Ray A. Retatrutide: a triple incretin receptor agonist for obesity management. *Expert Opin Investig Drugs*. 2023;32(11):1003-1008.
34. Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. *Nat Med*. 2025;31(1):278-285.
35. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. *Aliment Pharmacol Ther*. 2024;60(11–12):1525-1533.
36. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2023;389(12):1069-1084.
37. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. *The Lancet*. 2023;402(10401):529-544.
38. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2019;200(3):e6-24.
39. Li M, Lin H, Yang Q, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. *Sleep*. 2025;48(4):zsae280.
40. Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. *Endocrinology*. 2024;166(1):bqae155.
41. Zhang X, Wang M, Wang X, et al. Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis. *Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol*. 2022;28(3):333-341.
42. Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell*. 2019;177(3):587-596.e9.
43. Salmen T, Potcovaru CG, Bica IC, et al. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. *Pharmaceuticals*. 2024;17(10):1322.